Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Project Inform perspective

Showing results (211-220 of 280) with videos related to

Pageof 28
Sort By:
Project Inform Perspective|December 31, 2003
Interleukin-2: SILCAAT study to continue
Project Inform Perspective|May 4, 2004
General health maintenance strategies
Project Inform Perspective|May 4, 2004
Starting anti-HIV therapy
Project Inform Perspective|May 4, 2004
Third line anti-HIV therapy options
Project Inform Perspective|February 13, 2002
Drug level monitoring: the next advance in diagnostics
Project Inform Perspective|June 5, 2009
Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects
Project Inform Perspective|June 5, 2009
Prezista fares better than Kaletra in first line therapy
Project Inform Perspective|June 5, 2009
A person's modifiable risk factors nearly double their risk of non-AIDS death
Project Inform Perspective|March 3, 2009
Update from CROI 2008 on approved HIV drugsPaul Dalton
Project Inform Perspective|February 21, 2009
Switch to Viramune safe for some who can't tolerate Sustiva
Pageof 28

Showing results (211-220 of 280) with videos related to

Sort By:
Pageof 28
Project Inform Perspective|December 31, 2003
Interleukin-2: SILCAAT study to continue
Project Inform Perspective|May 4, 2004
General health maintenance strategies
Project Inform Perspective|May 4, 2004
Starting anti-HIV therapy
Project Inform Perspective|May 4, 2004
Third line anti-HIV therapy options
Project Inform Perspective|February 13, 2002
Drug level monitoring: the next advance in diagnostics
Project Inform Perspective|June 5, 2009
Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects
Project Inform Perspective|June 5, 2009
Prezista fares better than Kaletra in first line therapy
Project Inform Perspective|June 5, 2009
A person's modifiable risk factors nearly double their risk of non-AIDS death
Project Inform Perspective|March 3, 2009
Update from CROI 2008 on approved HIV drugsPaul Dalton
Project Inform Perspective|February 21, 2009
Switch to Viramune safe for some who can't tolerate Sustiva
Pageof 28